Mesoblast (FRA:LWB1) FFO


FRA:LWB1 Mesoblast Ltd FRA:LWB1
51 GF Score
Price €11.80
! 4 Warning Signs
View Full Analysis

What is Mesoblast FFO?

FFO (Funds from operations) only applies to REITs.

FRA:LWB1
51GF Score
Mesoblast Ltd FRA:LWB1
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
51GF Score

Get the complete analysis for FRA:LWB1

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.80
Price